Company Profiles

driven by the PitchBook Platform

Artielle ImmunoTherapeutics

Description

Provider of first-in-class platform of biologic drugs designed to treat degenerative diseases. The company's biologic drugs targets the CD74 receptor on monocytes and blocks the action of macro-phage migration inhibitory factor (MIF), enabling healthcare industry to treat neuroinflammatory and degenerative diseases including multiple sclerosis (MS), optic neuritis, methamphetamine addiction and stroke.

2004

Founded

PRIVATE

Status

1-10

Employees

Conv. Debt

Latest Deal Type

$285k

Latest Deal Amount

$15.7M

Total Amount Raised

Description

Provider of first-in-class platform of biologic drugs designed to treat degenerative diseases. The company's biologic drugs targets the CD74 receptor on monocytes and blocks the action of macro-phage migration inhibitory factor (MIF), enabling healthcare industry to treat neuroinflammatory and degenerative diseases including multiple sclerosis (MS), optic neuritis, methamphetamine addiction and stroke.

Website:

www.artielle.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

400 South El Camino Real Suite 1200 San Mateo, CA 94402United States +1 (650) 401-2000
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Artielle ImmunoTherapeutics's full profile, request a free trial.

    Artielle ImmunoTherapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Artielle ImmunoTherapeutics Investors (6)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Northwest Technology VenturesVenture CapitalMinority000 0000000 0000
    Pelion Venture PartnersVenture CapitalMinority000 0000000 0000
    Reference Capital ManagementVenture CapitalMinority000 0000000 0000
    Sanderling VenturesVenture CapitalMinority000 0000000 0000
    Tenex Greenhouse VenturesVenture CapitalMinority000 0000000 0000
    Northwest Technology Ventures Venture Capital
    Pelion Venture Partners Venture Capital
    Reference Capital Management Venture Capital
    Sanderling Ventures Venture Capital
    Tenex Greenhouse Ventures Venture Capital

    Artielle ImmunoTherapeutics Executive Team (5)

    NameTitleBoard
    Seat
    Contact
    Info
    Adolph Ferro Ph.DChief Executive Officer & President
    Gilbert MillerDirector & Secretary
    Peter McWilliams Ph.DChairman & Acting Chief Executive Officer
    John Metcalf Ph.DDirector
    Shahab FatheazamDirector
    Adolph Ferro Ph.D Chief Executive Officer & President
    Gilbert Miller Director & Secretary
    Peter McWilliams Ph.D Chairman & Acting Chief Executive Officer
    John Metcalf Ph.D Director
    Shahab Fatheazam Director

    Artielle ImmunoTherapeutics Board Members (1)

    NameRepresentingRoleSinceContact
    Info
    Peter McWilliams Ph.DSelfChairman & Acting Chief Executive Officer000 0000
    Peter McWilliams Ph.D Chairman & Acting Chief Executive Officer Self
    Request full access to PitchBook